Structure Therapeutics is a clinical-stage biopharmaceutical company that develops oral small molecule therapeutics for chronic metabolic diseases. Its approach is rooted in structure-based drug design and computational chemistry. The company's pipeline targets conditions with significant unmet medical needs.
The company completed its initial public offering in February 2023 and is listed on the NASDAQ under the ticker GPCR. It is led by a team of international drug innovators and is supported by global life sciences investors.
Structure Therapeutics maintains operations in South San Francisco, California, and Shanghai. Its stated focus is on transforming drug development to create more accessible medicines.
